Thursday, 5 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange

Latest announcements

Every corporate announcement our alert engine sent, newest first: orders, results, earnings calls, fund raises, board meetings and more.

21:06 IST BSE
Management ChangeAssam Entrade Ltd ASSAMENT

Assam Entrade Management Change

Assam Entrade Limited announced the resignation of M/s. Shivam Grover & Associates as Secretarial Auditor, effective April 28, 2026. The resignation is attributed to internal professional reasons, with no material concerns raised regarding management. The company's Audit Committee and Board will initiate the process to appoint a new Secretarial Auditor in due course.

21:15 IST BSE
Results UpdateEmmvee Photovoltaic Power Ltd EMMVEE

Emmvee Photovoltaic Power Results Update

Emmvee Photovoltaic Power Ltd reported FY2026 revenue of ₹5,049.9 Crore, up 116% year-on-year, while PAT tripled to ₹1,081.6 Crore. The company expanded module capacity to 10.3 GW and plans further expansion to 16.3 GW by FY2028. Strong performance was driven by solar cell operations and manufacturing scale benefits.

Value
₹5,050 Cr
21:14 IST BSE
Regulatory ApprovalOneSource Specialty Pharma Ltd ONESOURCE

OneSource Specialty Pharma Regulatory Approval

OneSource Specialty Pharma Limited received an EU GMP Certificate for its Sterile Product Division in Bangalore from German authorities. The certification follows an October 2025 inspection and covers aseptic liquids, secondary packing, and quality control. This approval complements existing US-FDA, Health Canada, ANVISA, and TGA clearances, strengthening the facility's global sterile manufacturing capabilities.

21:12 IST NSE
Results UpdateFive-Star Business Finance Ltd FIVESTAR

Five-Star Business Finance Results Update

Five-Star Business Finance reported its FY2026 results, achieving an 11% AUM growth to ₹13,225 Crore and a 2% PAT increase to ₹1,099 Crore. The company expanded its network to 844 branches, opening 9 new units during Q4. Despite asset quality headwinds, management noted improving collection efficiencies and expects 20% AUM growth for FY2027.

21:09 IST BSE
Financial ResultsPiramal Pharma Ltd PPLPHARMA

Piramal Pharma Financial Results

Piramal Pharma Limited reported its FY2026 audited financial results, showing standalone annual revenue of ₹4,782.01 Crore and PAT of ₹700.01 Crore. The Board also approved the re-appointment of Ms. Nandini Piramal as Chairperson and Mr. Peter DeYoung as Executive Director, alongside shifting the company's registered office and appointing a new Company Secretary.